Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafluprost
- Development stage
- Approved
- Lead developer
- Santen Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Tafluprost is a synthetic prostaglandin F2α analog used as an ophthalmic solution to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It acts as a selective agonist of the prostaglandin F receptor (FP receptor), increasing uveoscleral outflow of aqueous humor and thereby reducing IOP. Tafluprost is notable for its high affinity for the FP receptor—approximately 12 times that of latanoprost—and minimal activity at other receptors. The drug was jointly developed by Santen Pharmaceutical and Merck and is available in preservative-free formulations to improve tolerability. Common side effects include conjunctival hyperemia and possible irreversible changes such as iris pigmentation and eyelash growth[2][4][5].
- Brand names
- TaflotanZioptanTaprosSaflutan
- Other names
- 他氟前列素タフルプロスト
02
Targets
PTGER (Prostaglandin E2 receptor)PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on tafluprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafluprost.